Arcutis Biotherapeutics Inc [NASDAQ: ARQT] closed the trading session at $6.06. The company report on January 29, 2024 at 8:00 AM that Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial.
Novel steroid-free topical foam effectively controls seborrheic dermatitis.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Once-daily ZORYVE® (roflumilast) topical foam, 0.3%, is approved to treat seborrheic dermatitis in individuals 9 years of age and older.
The stocks have a year to date performance of 87.62 percent and weekly performance of 71.19 percent. The stock has been moved at -44.20 percent over the last six months. The stock has performed 100.66 percent around the most recent 30 days and changed 155.70 percent over the most recent 3-months.
If compared to the average trading volume of 4.99M shares, ARQT reached to a volume of 10942652 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Arcutis Biotherapeutics Inc [ARQT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ARQT shares is $12.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ARQT stock is a recommendation set at 1.57. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Mizuho have made an estimate for Arcutis Biotherapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 03, 2024.
The Average True Range (ATR) for Arcutis Biotherapeutics Inc is set at 0.47, with the Price to Sales ratio for ARQT stock in the period of the last 12 months amounting to 158.96. The Price to Book ratio for the last quarter was 8.02, with the Price to Cash per share for the same quarter was set at 2.36.
ARQT stock trade performance evaluation
Arcutis Biotherapeutics Inc [ARQT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 71.19. With this latest performance, ARQT shares gained by 100.66% in over the last four-week period, additionally sinking by -44.20% over the last 6 months – not to mention a drop of -62.36% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ARQT stock in for the last two-week period is set at 81.90, with the RSI for the last a single of trading hit 86.95, and the three-weeks RSI is set at 76.97 for Arcutis Biotherapeutics Inc [ARQT]. The present Moving Average for the last 50 days of trading for this stock 2.97, while it was recorded at 4.99 for the last single week of trading, and 6.94 for the last 200 days.
Arcutis Biotherapeutics Inc [ARQT]: An insightful look at the core fundamentals
Arcutis Biotherapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.39 and a Current Ratio set at 6.72.
Earnings per share (EPS) analysis for Arcutis Biotherapeutics Inc [ARQT] stock
With the latest financial reports released by the company, Arcutis Biotherapeutics Inc posted -1.18/share EPS, while the average EPS was predicted by analysts to be reported at -1.42/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 16.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ARQT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Arcutis Biotherapeutics Inc go to 9.80%.
Arcutis Biotherapeutics Inc [ARQT]: Institutional Ownership
The top three institutional holders of ARQT stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in ARQT stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in ARQT stock with ownership which is approximately 5.8325%.
